A faster return to growth for AstraZeneca?
This article was originally published in Scrip
Pascal Soriot, AstraZeneca's CEO, took his podium opportunity at the JP Morgan conference to have a quick swipe at GlaxoSmithKline over its problems in China, while trying to persuade the audience that AstraZeneca "can return to growth faster that most people have been forecasting."
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.